Back to search results

A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China

    Contact: Study coordinator (Zhitao Ying, Doctor of Medicine) · yingzhitao001@163.com · 010-67781331

  • Beijing GoBroad Boren Hospital, Beijing, Beijing Municipality, China

    Contact: Study coordinator (Yajing Zhang, Doctor of Medicine) · 23975701@qq.com · 010-83605002

  • Zhengzhou Yihe Hospital, Zhengzhou, Henan, China

    Contact: Study coordinator (Li Wang, Bachelor of Medicine) · zlyywl@qq.com · 0371-56570666

  • The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

    Contact: Study coordinator (Hongyan Tong, Doctor of Medicine) · hongyantong@aliyun.com · 0571-87235589
View source on ClinicalTrials.gov(opens in a new tab)